ILMN Illumina, Inc.
USHealthcareAs of 2026-10-08
Why ILMN matters now
Illumina, Inc. (ILMN) is a US stock in Healthcare. The latest InvestLog snapshot shows $264.40 with -1.25% on the session and $40.00B in market capitalization; recent performance reads 1-month +14.29% and YTD +23.46%.
The latest financial table shown here is Q1 2026, with revenue of $1.09B, net income of $134.0M, and EPS of $0.87. Investors can compare that operating picture with valuation signals such as P/E 21.75 and FCF yield 4.0%.
InvestLog's latest related AI research is a Rating Change note titled "Barclays raises ILMN target to $200 from $160". The latest indexable market news headline is "Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $152.50; recent insider activity includes Leckman Patricia filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
21.75
PEG
0.13
P/B
9.26
P/S
5.58
EV/EBITDA
18.43
DCF Value
$-56.66
FCF Yield
4.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
67.7%
Operating Margin
21.5%
Net Margin
19.4%
ROE
34.0%
ROA
13.0%
ROIC
13.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.09B | $134.0M | $0.87 |
| Q4 2025 | $1.16B | $334.0M | $2.17 |
| FY 2025 | $4.34B | $850.0M | $5.45 |
| Q3 2025 | $1.08B | $150.0M | $0.97 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$151.40
Target (Median)
$152.50
Target Range
$122.00 - $180.00
Trading Activity
Insider Trades
Related AI Research
Barclays raises ILMN target to $200 from $160Barclays 上调目标价 ILMN：$160 → $200
On 2026-10-07, Barclays raised its ILMN price target to $200 from $160 (+25.0%).Barclays 于 2026-10-07 将 ILMN 目标价上调至 $200，此前为 $160，变动幅度 +25.0%。
Guggenheim raises ILMN target to $305 from $226Guggenheim 上调目标价 ILMN：$226 → $305
On 2026-10-01, Guggenheim raised its ILMN price target to $305 from $226 (+35.0%).Guggenheim 于 2026-10-01 将 ILMN 目标价上调至 $305，此前为 $226，变动幅度 +35.0%。
Leerink raises ILMN target to $300 from $220Leerink 上调目标价 ILMN：$220 → $300
On 2026-09-29, Leerink raised its ILMN price target to $300 from $220 (+36.4%).Leerink 于 2026-09-29 将 ILMN 目标价上调至 $300，此前为 $220，变动幅度 +36.4%。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
1.49
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.